Bertil Lindahl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5169607/publications.pdf

Version: 2024-02-01

168 papers	16,015 citations	44069 48 h-index	16650 123 g-index
169 all docs	169 docs citations	169 times ranked	17602 citing authors

#	Article	IF	Citations
1	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
2	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
3	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	2.2	2,447
4	The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Heart, 2010, 96, 1617-1621.	2.9	537
5	Recommendations for the use of cardiac troponin measurement in acute cardiac care. European Heart Journal, 2010, 31, 2197-2204.	2.2	533
6	Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease. Circulation, 2017, 135, 1481-1489.	1.6	316
7	Improved outcomes in patients with ST-elevation myocardial infarction during the last 20â€‰years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995â€“2014. European Heart Journal, 2017, 38, 3056-3065.	2.2	302
8	Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T. Annals of Emergency Medicine, 2016, 68, 76-87.e4.	0.6	294
9	Oxygen Therapy in Suspected Acute Myocardial Infarction. New England Journal of Medicine, 2017, 377, 1240-1249.	27.0	276
10	IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. Clinical Biochemistry, 2015, 48, 201-203.	1.9	224
11	Periodontitis Increases the Risk of a First Myocardial Infarction. Circulation, 2016, 133, 576-583.	1.6	200
12	How is cardiac troponin released from injured myocardium?. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 553-560.	1.0	179
13	Î²-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. Journal of the American College of Cardiology, 2017, 69, 2710-2720.	2.8	174
14	Type 2 myocardial infarction in clinical practice. Heart, 2015, 101, 101-106.	2.9	172
15	Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial. Lancet, The, 2019, 393, 133-142.	13.7	142
16	Persistent Cardiac Troponin I Elevation in Stabilized Patients After an Episode of Acute Coronary Syndrome Predicts Long-Term Mortality. Circulation, 2007, 116, 1907-1914.	1.6	136
17	Sex Differences in Treatments, Relative Survival, and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART Registry. Journal of the American Heart Association, 2017, 6, .	3.7	134
18	The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: The FRISC II invasive troponin T electrocardiogram substudy. American Heart Journal, 2002, 143, 760-767.	2.7	121

#	Article	IF	Citations
19	Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with nonâ€“ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology, 2005, 45, 533-541.	2.8	115
20	Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. European Heart Journal, 2018, 39, 3766-3776.	2.2	112
21	Cardiac Troponin I Levels Measured With a High-Sensitive Assay Increase Over Time and Are Strong Predictors of Mortality in an Elderly Population. Journal of the American College of Cardiology, 2013, 61, 1906-1913.	2.8	111
22	Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis. Atherosclerosis, 2015, 242, 205-210.	0.8	108
23	A 1-h Combination Algorithm Allows FastÂRule-Out and Rule-In of MajorÂAdverse Cardiac Events. Journal of the American College of Cardiology, 2016, 67, 1531-1540.	2.8	102
24	Diagnostic and prognostic implications using age- and gender-specific cut-offs for high-sensitivity cardiac troponin T â€" Sub-analysis from the TRAPID-AMI study. International Journal of Cardiology, 2016, 209, 26-33.	1.7	101
25	Possible mechanisms behind cardiac troponin elevations. Biomarkers, 2018, 23, 725-734.	1.9	95
26	The new high-sensitivity cardiac troponin T assay improves risk assessment in acute coronary syndromes. American Heart Journal, 2010, 160, 224-229.	2.7	92
27	Small Changes in Troponin T Levels Are Common in Patients With Nonâ€“ST-Segment Elevation Myocardial Infarction and Are Linked to Higher Mortality. Journal of the American College of Cardiology, 2013, 62, 1231-1238.	2.8	88
28	Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. European Heart Journal, 2021, 42, 243-252.	2.2	84
29	Impact of age on the performance of the ESC 0/1h-algorithms for early diagnosis of myocardial infarction. European Heart Journal, 2018, 39, 3780-3794.	2.2	78
30	Cardiac Troponin Elevation in PatientsÂWithout a Specific Diagnosis. Journal of the American College of Cardiology, 2019, 73, 1-9.	2.8	74
31	Discovery of New Risk Markers for Ischemic Stroke Using a Novel Targeted Proteomics Chip. Stroke, 2015, 46, 3340-3347.	2.0	71
32	Rapid rule out of acute myocardial infarction: novel biomarker-based strategies. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 218-222.	1.0	70
33	Impact on Long-Term Mortality of Presence of Obstructive Coronary Artery Disease and Classification of Myocardial Infarction. American Journal of Medicine, 2016, 129, 398-406.	1.5	69
34	Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet, The, 2016, 388, 1903-1911.	13.7	68
35	Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome. Circulation, 2020, 142, 1700-1708.	1.6	68
36	Implications of Introducing High-Sensitivity Cardiac Troponin T IntoÂClinical Practice. Journal of the American College of Cardiology, 2015, 65, 1655-1664.	2.8	67

#	Article	IF	Citations
37	Short- and Long-term Individual Variation in Cardiac Troponin in Patients with Stable Coronary Artery Disease. Clinical Chemistry, 2013, 59, 401-409.	3.2	66
38	What to do when you question cardiac troponin values. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 577-586.	1.0	66
39	The Use of Very Low Concentrations of Highâ€sensitivity Troponin T to Rule Out Acute Myocardial Infarction Using a Single Blood Test. Academic Emergency Medicine, 2016, 23, 1004-1013.	1.8	64
40	Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	64
41	The applied statistical approach highly influences the 99th percentile of cardiac troponin I. Clinical Biochemistry, 2016, 49, 1109-1112.	1.9	62
42	How to use D-dimer in acute cardiovascular care. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 69-80.	1.0	60
43	Discontinuation of Smokeless Tobacco and Mortality Risk After Myocardial Infarction. Circulation, 2014, 130, 325-332.	1.6	59
44	Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: Data from the SWEDEHEART registry. European Journal of Preventive Cardiology, 2016, 23, 340-348.	1.8	58
45	Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart, 2014, 1, e000002.	2.3	56
46	DETermination of the role of OXygen in suspected Acute Myocardial Infarction trial. American Heart Journal, 2014, 167, 322-328.	2.7	56
47	Revision of the Troponin T Release Mechanism from Damaged Human Myocardium. Clinical Chemistry, 2014, 60, 1098-1104.	3.2	51
48	High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. American Heart Journal, 2013, 166, 541-548.e1.	2.7	50
49	Early diagnosis of acute coronary syndrome. European Heart Journal, 2017, 38, 3049-3055.	2.2	50
50	Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design. American Heart Journal, 2021, 231, 96-104.	2.7	49
51	Economic evaluation of the one-hour rule-out and rule-in algorithm for acute myocardial infarction using the high-sensitivity cardiac troponin T assay in the emergency department. PLoS ONE, 2017, 12, e0187662.	2.5	48
52	Use of copeptin for rapid rule-out of acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 570-576.	1.0	47
53	Myocardial infarction with non-obstructive coronary artery disease. EuroIntervention, 2021, 17, e875-e887.	3.2	47
54	Î²â€Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study. Journal of the American Heart Association, 2015, 4, .	3.7	46

#	Article	IF	Citations
55	Reinfarction in Patients with Myocardial Infarction with Nonobstructive Coronary Arteries (MINOCA): Coronary Findings and Prognosis. American Journal of Medicine, 2019, 132, 335-346.	1.5	45
56	Survival in Patients With Suspected Myocardial Infarction With Nonobstructive Coronary Arteries: A Comprehensive Systematic Review and Meta-Analysis From the MINOCA Global Collaboration. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007880.	2.2	45
57	The Story of Growth Differentiation Factor 15: Another Piece of the Puzzle. Clinical Chemistry, 2013, 59, 1550-1552.	3.2	44
58	Cardiac troponin I levels in patients with nonâ€“ST-elevation acute coronary syndromeâ€”The importance of gender. American Heart Journal, 2014, 168, 317-324.e1.	2.7	44
59	Unstable Angina in the Era of Cardiac Troponin Assays with Improved Sensitivityâ€”A Clinical Dilemma. American Journal of Medicine, 2017, 130, 1423-1430.e5.	1.5	44
60	Christmas, national holidays, sport events, and time factors as triggers of acute myocardial infarction: SWEDEHEART observational study 1998-2013. BMJ: British Medical Journal, 2018, 363, k4811.	2.3	44
61	Cardiovascular biomarkers in patients with COVID-19. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 310-319.	1.0	44
62	Long-Term Outcome of Incomplete Revascularization After Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). JACC: Cardiovascular Interventions, 2016, 9, 207-215.	2.9	43
63	NT-proBNP is a powerful predictor for incident atrial fibrillation â€” Validation of a multimarker approach. International Journal of Cardiology, 2016, 223, 74-81.	1.7	42
64	New Generation Cardiac Troponin I Assay for the Access Immunoassay System. Clinical Chemistry, 2001, 47, 959-961.	3.2	40
65	Type 2 myocardial infarction: the chimaera of cardiology?. Heart, 2015, 101, 1697-1703.	2.9	40
66	Impact of Sex on Cardiac Troponin Concentrationsâ€”A Critical Appraisal. Clinical Chemistry, 2017, 63, 1457-1464.	3.2	40
67	Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic. Heart, 2020, 106, 1812-1818.	2.9	40
68	Interphysician agreement on subclassification of myocardial infarction. Heart, 2018, 104, 1284-1291.	2.9	38
69	A Rule-Out Strategy Based on High-Sensitivity Troponin and HEART Score Reduces Hospital Admissions. Annals of Emergency Medicine, 2019, 73, 491-499.	0.6	38
70	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. Clinical Chemistry, 2015, 61, 368-378.	3.2	37
71	Why all the struggle about CK-MB and PCI?. European Heart Journal, 2012, 33, 1046-1048.	2.2	36
72	The Liver and Kidneys mediate clearance of cardiac troponin in the rat. Scientific Reports, 2020, 10, 6791.	3.3	34

#	Article	IF	Citations
73	Serial Sampling of High-Sensitivity Cardiac Troponin T May Not Be Required for Prediction of Acute Myocardial Infarction Diagnosis in Chest Pain Patients with Highly Abnormal Concentrations at Presentation. Clinical Chemistry, 2017, 63, 542-551.	3.2	33
74	Editorâ€™s Choice-Rule-in of acute myocardial infarction: Focus on troponin. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 212-217.	1.0	32
75	Oxygen therapy in ST-elevation myocardial infarction. European Heart Journal, 2018, 39, 2730-2739.	2.2	32
76	Statistics on mortality following acute myocardial infarction in 842â€‰897 Europeans. Cardiovascular Research, 2020, 116, 149-157.	3.8	31
77	In search for the Holy Grail: Suggestions for studies to define delta changes to diagnose or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Care Association. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 313-316.	1.0	30
78	Prognosis in relation to high-sensitivity cardiac troponin T levels in patients with myocardial infarction and non-obstructive coronary arteries. American Heart Journal, 2018, 200, 60-66.	2.7	30
79	Diagnostic Accuracy of High-Sensitivity Cardiac Troponin T at Presentation Combined With History and ECG for Ruling Out Major Adverse Cardiac Events. Annals of Emergency Medicine, 2016, 68, 649-658.e3.	0.6	28
80	A Possible Mechanism behind Faster Clearance and Higher Peak Concentrations of Cardiac Troponin I Compared with Troponin T in Acute Myocardial Infarction. Clinical Chemistry, 2020, 66, 333-341.	3.2	28
81	Prognostic Importance of Sex-Specific Cardiac Troponin T 99th Percentiles in Suspected Acute Coronary Syndrome. American Journal of Medicine, 2016, 129, 880.e1-880.e12.	1.5	27
82	A 0â€Hour/1â€Hour Protocol for Safe, Early Discharge of Chest Pain Patients. Academic Emergency Medicine, 2017, 24, 983-992.	1.8	26
83	Combined testing of copeptin and high-sensitivity cardiac troponin T at presentation in comparison to other algorithms for rapid rule-out of acute myocardial infarction. International Journal of Cardiology, 2019, 276, 261-267.	1.7	25
84	Novel Criteria for the Observe-Zone of the ESC 0/1h-hs-cTnT Algorithm. Circulation, 2021, 144, 773-787.	1.6	25
85	Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?. European Heart Journal: Acute Cardiovascular Care, 2017, 6, 321-328.	1.0	23
86	ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB. European Heart Journal, 2021, 42, 2260-2264.	2.2	23
87	Pregnancy Complications and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study. Journal of the American Heart Association, 2022, 11, e023079.	3.7	23
88	Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction. Circulation, 2018, 138, 2754-2762.	1.6	22
89	High-Sensitivity Cardiac Troponin-Based Strategies for the Assessment of Chest Pain Patientsâ€”A Review of Validation and Clinical Implementation Studies. Clinical Chemistry, 2018, 64, 1572-1585.	3.2	22
90	Autoantibodies to cardiac troponin in acute coronary syndromes. Clinica Chimica Acta, 2010, 411, 1793-1798.	1.1	21

#	Article	IF	Citations
91	The beneficial effect over 3 years by pictorial information to patients and their physician about subclinical atherosclerosis and cardiovascular risk: Results from the VIPVIZA randomized clinical trial. American Journal of Preventive Cardiology, 2021, 7, 100199.	3.0	21
92	Increased risk of heart failure in women with symptoms of sleep-disordered breathing. Sleep Medicine, 2016, 17, 32-37.	1.6	20
93	Evaluation of Temporal Changes in Cardiovascular Biomarker Concentrations Improves Risk Prediction in an Elderly Population from the Community. Clinical Chemistry, 2016, 62, 485-493.	3.2	17
94	Elevation of cardiac troponins measured after recreational resistance training. Clinical Biochemistry, 2015, 48, 803-806.	1.9	16
95	Inequity of access to ACE inhibitors in Swedish heart failure patients: a register-based study. Journal of Epidemiology and Community Health, 2016, 70, 97-103.	3.7	16
96	Circadian onset and prognosis of myocardial infarction with non-obstructive coronary arteries (MINOCA). PLoS ONE, 2019, 14, e0216073.	2.5	16
97	Variations on classification of main types of myocardial infarction: a systematic review and outcome meta-analysis. Clinical Research in Cardiology, 2019, 108, 749-762.	3.3	16
98	Sex-specific effects of implementing a high-sensitivity troponin I assay in patients with suspected acute coronary syndrome: results from SWEDEHEART registry. Scientific Reports, 2020, 10, 15227.	3.3	16
99	Development and validation of an artificial neural network algorithm to predict mortality and admission to hospital for heart failure after myocardial infarction: a nationwide population-based study. The Lancet Digital Health, 2022, 4, e37-e45.	12.3	16
100	The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients. Upsala Journal of Medical Sciences, 2017, 122, 224-233.	0.9	15
101	Effect of Oxygen Therapy on Cardiovascular Outcomes in Relation to Baseline Oxygen Saturation. JACC: Cardiovascular Interventions, 2020, 13, 502-513.	2.9	15
102	Prasugrel versus ticagrelor in patients with myocardial infarction undergoing percutaneous coronary intervention. Heart, 2021, 107, 1145-1151.	2.9	15
103	The SWEDEHEART secondary prevention and cardiac rehabilitation registry (SWEDEHEART CR registry). European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 431-437.	4.0	15
104	Differences in biomarker concentrations and predictions of long-term outcome in patients with ST-elevation and non-ST-elevation myocardial infarction. Clinical Biochemistry, 2021, 98, 17-23.	1.9	15
105	Short- and long-term individual variation in NT-proBNP levels in patients with stable coronary artery disease. Clinica Chimica Acta, 2013, 422, 15-20.	1.1	14
106	Unrecognized Myocardial Infarction Assessed by Cardiac Magnetic Resonance Imaging â€“ Prognostic Implications. PLoS ONE, 2016, 11, e0148803.	2.5	14
107	The composition and daily variation of microparticles in whole blood in stable coronary artery disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 25-32.	1.2	14
108	Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer and Prostatic Diseases, 2020, 23, 527-533.	3.9	14

#	Article	IF	Citations
109	Myocardial Infarction with Nonobstructive Coronary Arteries: The Importance of Achieving Secondary Prevention Targets. American Journal of Medicine, 2018, 131, 524-531.e6.	1.5	13
110	Two-hour diagnostic algorithms for early assessment of patients with acute chest pain â€" Implications of lowering the cardiac troponin I cut-off to the 97.5th percentile. Clinica Chimica Acta, 2015, 445, 19-24.	1.1	12
111	Sex-differences in circulating biomarkers during acute myocardial infarction: An analysis from the SWEDEHEART registry. PLoS ONE, 2021, 16, e0249830.	2.5	12
112	Cardiac Biomarkers. Disease Markers, 2015, 2015, 1-3.	1.3	11
113	Cardiac Troponins and Their Prognostic Importance in Patients with Suspected Acute Coronary Syndrome and Renal Dysfunction. Clinical Chemistry, 2017, 63, 1409-1417.	3.2	11
114	Unrecognized myocardial infarction assessed by cardiac magnetic resonance imaging is associated with adverse long-term prognosis. PLoS ONE, 2018, 13, e0200381.	2.5	11
115	Target-Attainment Rates of Low-Density Lipoprotein Cholesterol Using Lipid-Lowering Drugs One Year After Acute Myocardial Infarction in Sweden. American Journal of Cardiology, 2014, 113, 17-22.	1.6	10
116	Unrecognized myocardial infarctions assessed by cardiovascular magnetic resonance are associated with the severity of the stenosis in the supplying coronary artery. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 98.	3.3	10
117	Quantitation of 87 Proteins by nLC-MRM/MS in Human Plasma: Workflow for Large-Scale Analysis of Biobank Samples. Journal of Proteome Research, 2017, 16, 3242-3254.	3.7	10
118	Predictive Value of High-Sensitivity Troponin T for Systolic Dysfunction and Infarct Size (Six Months) After ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2018, 122, 735-743.	1.6	10
119	Diagnosing type 2 myocardial infarction in clinical routine. A validation study. Scandinavian Cardiovascular Journal, 2019, 53, 259-265.	1.2	10
120	Sensitivity of undetectable level of high-sensitivity troponin T at presentation in a large non-ST-segment elevation myocardial infarction cohort of early presenters. International Journal of Cardiology, 2019, 284, 6-11.	1.7	10
121	Benchmarking Observational Analyses Before Using Them to Address Questions Trials Do Not Answer: An Application to Coronary Thrombus Aspiration. American Journal of Epidemiology, 2022, 191, 1652-1665.	3.4	10
122	Cardiac Troponin I Associated with the Development of Unrecognized Myocardial Infarctions Detected with MRI. Clinical Chemistry, 2014, 60, 1327-1335.	3.2	9
123	Predictors of 10-year changes in levels of N-terminal pro B-type natriuretic peptide and cardiac troponin I in the elderly. International Journal of Cardiology, 2018, 257, 300-305.	1.7	9
124	Aiming toWards Evidence baSed inTerpretation of Cardiac biOmarkers in patients pResenting with chest pain-the WESTCOR study: study design. Scandinavian Cardiovascular Journal, 2019, 53, 280-285.	1.2	9
125	Sex differences in investigations and outcomes among patients with type 2 myocardial infarction. Heart, 2021, 107, 1480-1486.	2.9	9
126	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 343-355.	1.0	9

#	Article	IF	Citations
127	Relation between Cardiovascular Disease Risk Markers and Brain Infarcts Detected by Magnetic Resonance Imaging in an Elderly Population. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 312-318.	1.6	8
128	Oxygen therapy in suspected acute myocardial infarction and concurrent normoxemic chronic obstructive pulmonary disease: a prespecified subgroup analysis from the DETO2X-AMI trial. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 984-992.	1.0	8
129	Timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from the nationwide SWEDEHEART registry. EuroIntervention, 2022, 18, 582-589.	3.2	8
130	Are There Really Biomarkers of Vulnerable Plaque?. Clinical Chemistry, 2012, 58, 151-153.	3.2	7
131	Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial. Diabetes Care, 2019, 42, 2032-2041.	8.6	7
132	Symptoms Predictive of Acute Myocardial Infarction in the Troponin Era: Analysis From the TRAPID-AMI Study. Critical Pathways in Cardiology, 2019, 18, 10-15.	0.5	7
133	Clinical and prognostic implications of Câ€reactive protein levels in myocardial infarction with nonobstructive coronary arteries. Clinical Cardiology, 2021, 44, 1019-1027.	1.8	7
134	Predicting outcome in acute myocardial infarction: an analysis investigating 175 circulating biomarkers. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 806-812.	1.0	7
135	Treatment and Prognosis of Myocardial Infarction Outside Cardiology Departments. Journal of Clinical Medicine, 2021, 10, 106.	2.4	7
136	The ratio of cardiac troponin T to troponin I may indicate non-necrotic troponin release among COVID-19 patients. Clinica Chimica Acta, 2022, 527, 33-37.	1.1	7
137	Routine Oxygen Therapy Does Not Improve Health-Related Quality of Life in Patients With Acute Myocardial Infarctionâ€"Insights From the Randomized DETO2X-AMI Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 638829.	2.4	6
138	Clinical risk scores identify more patients at risk for cardiovascular events within 30 days as compared to standard ACS risk criteria: the WESTCOR study. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 287-301.	1.0	6
139	Unrecognized myocardial scars detected by delayedâ€"enhanced MRI are associated with increased levels of NT-proBNP. Coronary Artery Disease, 2011, 22, 158-164.	0.7	5
140	Effectiveness and Safety of the European Society of Cardiology 0-/1-h Troponin Rule-Out Protocol: The Design of the ESC-TROP Multicenter Implementation Study. Cardiology, 2020, 145, 685-692.	1.4	5
141	Non-employment and low educational level as risk factors for inequitable treatment and mortality in heart failure: a population-based cohort study of register data. BMC Public Health, 2021, 21, 1040.	2.9	5
142	Influence of health-related quality of life on time from symptom onset to hospital arrival and the risk of readmission in patients with myocardial infarction. Open Heart, 2014, 1, e000051.	2.3	4
143	Unrecognized myocardial infarctions detected by cardiac magnetic resonance imaging are associated with cardiac troponin I levels. Clinica Chimica Acta, 2016, 455, 189-194.	1.1	4
144	Sex differences in sickness absence and the morbidity-mortality paradox: a longitudinal study using Swedish administrative registers. BMJ Open, 2019, 9, e024098.	1.9	4

#	Article	IF	Citations
145	Novel clearance of muscle proteins by muscle cells. European Journal of Cell Biology, 2020, 99, 151127.	3.6	4
146	Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study. Frontiers in Oncology, 2020, 10, 571838.	2.8	4
147	Plasma-derived extracellular vesicles from myocardial infarction patients inhibits tumor necrosis factor-alpha induced cardiac cell death. Current Research in Translational Medicine, 2022, 70, 103323.	1.8	4
148	Strong development of research based on national quality registries in Sweden. Upsala Journal of Medical Sciences, 2019, 124, 9-11.	0.9	3
149	Biobank linked to SWEDEHEART quality registryâ€"routine blood sample collection opens new opportunities for cardiovascular research. Upsala Journal of Medical Sciences, 2019, 124, 12-15.	0.9	3
150	Randomized Evaluation of Beta Blocker and ACE-Inhibitor/Angiotensin Receptor Blocker Treatment for Post Infarct Angina in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries: A MINOCA-BAT Sub Study Rationale and Design. Frontiers in Cardiovascular Medicine, 2021, 8, 717526.	2.4	3
151	Reliability of estimating left ventricular ejection fraction in clinical routine: a validation study of the SWEDEHEART registry. Clinical Research in Cardiology, 2023, 112, 68-74.	3.3	3
152	The clinical approach to diagnosing peri-procedural myocardial infarction after percutaneous coronary interventions according to the fourth universal definition of myocardial infarction â€“ from the study group on biomarkers of the European Society of Cardiology (ESC) Association for Acute CardioVascular Care (ACVC). Biomarkers, 2022, 27, 407-417.	1.9	3
153	Therapeutic implications of the use of cardiac markers in acute coronary syndromes. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 43-49.	1.2	2
154	Diagnosis and Management of Patients with Suspected Acute Myocardial Infarction. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 93-98.	1.2	2
155	Response by Lindahl et al to Letter Regarding Article, â€œMedical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Diseaseâ€• Circulation, 2017, 136, 1082-1083.	1.6	2
156	Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease. JRSM Cardiovascular Disease, 2019, 8, 204800401984197.	0.7	2
157	Application of the fourth universal definition of myocardial infarction in clinical practice. Biomarkers, 2020, 25, 322-330.	1.9	2
158	Prognostic Utility of a Modified HEART Score When Different Troponin Cut Points Are Used. Critical Pathways in Cardiology, 2021, 20, 134-139.	0.5	2
159	Randomized comparison of early supplemental oxygen versus ambient air in patients with confirmed myocardial infarction: Sex-related outcomes from DETO2X-AMI. American Heart Journal, 2021, 237, 13-24.	2.7	2
160	Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 353-360.	1.2	2
161	OUP accepted manuscript. Clinical Chemistry, 2021, 67, 1732-1734.	3.2	1
162	Myocardial infarction after elective percutaneous coronary interventionâ€"which cardiac troponin cut-off to use?. European Heart Journal, 2021, , .	2.2	1

#	Article	IF	Citations
163	Blood and imaging biomarkers in type 2 myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 269-271.	1.0	1
164	Response to Letter Regarding Article, â€œDiscontinuation of Smokeless Tobacco and Mortality Risk After Myocardial Infarctionâ€. Circulation, 2015, 131, e423.	1.6	0
165	In reply:. Annals of Emergency Medicine, 2016, 67, 794-795.	0.6	0
166	The Reply. American Journal of Medicine, 2017, 130, e417-e418.	1.5	0
167	Do self-reported pregnancy complications add to risk evaluation in older women with established cardiovascular disease?. BMC Women's Health, 2019, 19, 160.	2.0	0
168	Avoiding Routine Oxygen Therapy in Patients With Myocardial Infarction Saves Significant Expenditure for the Health Care Systemâ€”Insights From the Randomized DETO2X-AMI Trial. Frontiers in Public Health, 2021, 9, 711222.	2.7	0